Comparison Between Oral Methotrexate and Tofacitinib in Chronic Plaque Psoriasis

Recruiting now · Early Phase 1

Conditions studied: Psoriasis

In brief

Psoriasis is a chronic inflammatory dermatoses which include well demarcated scaly erythematous plaques on whole body including scalp role of methotrexate vs tofacitinib is compared in this study

Key facts

Study ID

NCT07261306

Run by

Lahore General Hospital

People needed

75

Starts

2025-08-29

Expected to finish

2025-12-25

Last updated by the study team

2025-12-03

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Patients aged 18- 70 years of either gender.
• Only patients with Psoriasis Area and Severity Index (PASI) score of 10 or above, and/or Body Surface Area (BSA) involvement of 10% or more, will be included.
• Duration of plaque psoriasis for at least 6 months prior to the study.
• Psoriasis that has not shown adequate response to topical therapies

You may not qualify if…

• Individuals with other forms of psoriasis or other significant dermatological conditions that might interfere with the assessment of psoriasis.
• Participants currently receiving systemic corticosteroids, biologics, or any other immunosuppressive agents within 4 weeks prior to the start of the study will be excluded.
• Known hypersensitivity or contraindications to either methotrexate or tofacitinib.
• History of significant liver, kidney, hematologic/bleeding disorder, gastrointestinal/acid peptic disease, or immune system disorders.and any history of tuberculosis and malignancy.
• Pregnant or lactating women will not be eligible for the study.

Where it is running

• Lahore general hospital — Lahore, Punjab Province, Pakistan (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.